10-Year Outcomes of Stents Versus Coronary Artery Bypass Grafting for Left Main Coronary Artery Disease.

[1]  V. Fuster,et al.  Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data , 2018, The Lancet.

[2]  Seung‐Jung Park,et al.  Safety and Effectiveness of Second-Generation Drug-Eluting Stents in Patients With Left Main Coronary Artery Disease. , 2018, Journal of the American College of Cardiology.

[3]  Seung‐Jung Park,et al.  Percutaneous Coronary Intervention of Left Main Disease: Pre- and Post-EXCEL (Evaluation of XIENCE Everolimus Eluting Stent Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) and NOBLE (Nordic-Baltic-British Left Main Revascularization Study) Era , 2017, Circulation. Cardiovascular interventions.

[4]  J. Hartikainen,et al.  Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial , 2016, The Lancet.

[5]  S. Pocock,et al.  Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. , 2016, The New England journal of medicine.

[6]  Seung‐Jung Park,et al.  Left Main Coronary Artery Disease: Secular Trends in Patient Characteristics, Treatments, and Outcomes. , 2016, Journal of the American College of Cardiology.

[7]  John H. Alexander,et al.  Coronary-Artery Bypass Grafting. , 2016, The New England journal of medicine.

[8]  P. Serruys,et al.  Outcomes After Percutaneous Coronary Intervention or Bypass Surgery in Patients With Unprotected Left Main Disease. , 2016, Journal of the American College of Cardiology.

[9]  J. Rouleau,et al.  Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. , 2016, The New England journal of medicine.

[10]  Jack L. Martin,et al.  Left Main Stenting in Comparison With Surgical Revascularization: 10-Year Outcomes of the (Left Main Coronary Artery Stenting) LE MANS Trial. , 2016, JACC. Cardiovascular interventions.

[11]  M. Jeong,et al.  Randomized Trial of Stents Versus Bypass Surgery for Left Main Coronary Artery Disease: 5-Year Outcomes of the PRECOMBAT Study. , 2015, Journal of the American College of Cardiology.

[12]  M. Mack,et al.  Five-Year Outcomes in Patients With Left Main Disease Treated With Either Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery Trial , 2014, Circulation.

[13]  Antonio Colombo,et al.  Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial , 2013, The Lancet.

[14]  M. Jeong,et al.  Everolimus-eluting stent implantation for unprotected left main coronary artery stenosis. The PRECOMBAT-2 (Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease) study. , 2012, JACC. Cardiovascular interventions.

[15]  Sean M. O'Brien,et al.  Comparative effectiveness of revascularization strategies. , 2012, The New England journal of medicine.

[16]  Seung‐Jung Park,et al.  Complexity of atherosclerotic coronary artery disease and long-term outcomes in patients with unprotected left main disease treated with drug-eluting stents or coronary artery bypass grafting. , 2011, Journal of the American College of Cardiology.

[17]  C. O'connor,et al.  Coronary-artery bypass surgery in patients with left ventricular dysfunction. , 2011, The New England journal of medicine.

[18]  Seung‐Jung Park,et al.  Clinical ResearchInterventional CardiologyLong-Term Outcomes After Stenting Versus Coronary Artery Bypass Grafting for Unprotected Left Main Coronary Artery Disease: 10-Year Results of Bare-Metal Stents and 5-Year Results of Drug-Eluting Stents From the ASAN–MAIN (ASAN Medical Center–Left MAIN Revas , 2010 .

[19]  M. Jeong,et al.  Long-term safety and efficacy of stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: 5-year results from the MAIN-COMPARE (Revascularization for Unprotected Left Main Coronary Artery Stenosis: Comparison of Percutaneous Coronary Angioplasty Versus Surgi , 2010, Journal of the American College of Cardiology.

[20]  Young-Hak Kim,et al.  Stents versus coronary-artery bypass grafting for left main coronary artery disease. , 2008, The New England journal of medicine.

[21]  Seung‐Jung Park,et al.  Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis: comparison with bare metal stent implantation. , 2005, Journal of the American College of Cardiology.

[22]  Seung‐Jung Park,et al.  Elective stenting of unprotected left main coronary artery stenosis: effect of debulking before stenting and intravascular ultrasound guidance. , 2001, Journal of the American College of Cardiology.

[23]  J. Robins,et al.  Marginal Structural Models and Causal Inference in Epidemiology , 2000, Epidemiology.

[24]  R. Lang,et al.  Left Main Coronary Artery Disease , 1998 .

[25]  P. Rosenbaum.  Model-Based Direct Adjustment , 1987 .

[26]  P. Kolh,et al.  2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Ca , 2014, European heart journal.

[27]  Seung‐Jung Park,et al.  Stenting of unprotected left main coronary artery stenoses: immediate and late outcomes. , 1998, Journal of the American College of Cardiology.

[28]  Volkmar Falk,et al.  Guidelines on Myocardial Revascularization the Task Force on Myocardial Revascularization of the European Society of Cardiology (esc) and the European Association for Cardio-thoracic Surgery (eacts) Developed with the Special Contribution of the European Association for Percutaneous Cardiovascular I , 2022 .